Curadev's CRD3874-SI Phase 1a/b Trial Completes First Patient's Treatment Cycle at MSKCC

Curadev Pharma has achieved a crucial step in its cancer treatment research with the successful completion of the initial treatment phase for a patient administered CRD3874-SI, a novel small molecule that targets the STING receptor to stimulate the immune system against cancer. The Phase 1a/b clinical trial, taking place at the Memorial Sloan Kettering Cancer Center in New York, marks the first instance of intravenously administering the STING agonist to patients with advanced sarcoma and Merkel cell carcinoma. The primary aim of the dose-escalation phase is to assess the safety profile and tolerability of the drug, with the goal of determining the maximum tolerated dose and the recommended dose for Phase 2 trials.

Dr. Arjun Surya, Curadev's CEO and Chief Scientific Officer, highlighted the significance of this milestone, noting that CRD3874-SI is a leading product from a comprehensive drug discovery initiative. The compound is unique among STING agonists due to its allosteric binding, which is distinct from agonists that bind to the orthosteric CDN site. Positive data from preclinical studies, including the drug's efficacy in human STING knock-in mice and safety in non-human primates, were previously presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, paving the way for the FDA's approval of the first-in-human trials.

Dr. Ciara Kelly, Principal Investigator of the trial and a specialist in sarcoma and Merkel cell carcinoma, expressed optimism about CRD3874-SI's potential to enhance the body's innate and adaptive immune responses, offering a new therapeutic option for patients with advanced cancers. The clinical trial is a testament to Curadev's dedication to developing transformative cancer treatments, as stated by Dr. Surya.

Curadev, a clinical-stage biotech firm, is focused on the discovery and development of innovative small molecule therapies for challenging diseases. The company's target-centric approach and innovative research programs have led to a robust pipeline of drug candidates aimed at next-generation drug targets.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!